• Actuate Therapeutics posted a net loss of $5.63 million for the quarter ended March 31, 2026, narrowing from $6.32 million a year earlier.
• Operating loss improved to $5.71 million as total operating expenses fell to $5.71 million from $6.37 million.
• Research and development expense dropped to $2.57 million from $3.22 million, due to lower external clinical study costs and lower CMC spending.
• Cash and cash equivalents totaled $8.13 million at March 31, with management estimating funds will not cover operating and capital needs beyond July 2026 without additional financing.
• Pipeline update: FDA cleared a Phase 1/2 study for the oral elraglusib tablet following an IND filing in April 2026, while updated Phase 2 mPDAC data presented in January 2026 showed median overall survival of 10.1 months with elraglusib plus GnP versus 7.2 months for GnP alone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-003909), on May 14, 2026, and is solely responsible for the information contained therein.